Final Approval In Glumetza Antitrust Deal Gives Attys $50M

By J. Edward Moreno · February 4, 2022, 5:22 PM EST

A California federal judge granted final approval of three settlements resolving direct buyers' class claims that drugmakers plotted to delay the generic version of the blockbuster diabetes drug Glumetza, awarding $50 million...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In Re Glumetza Antitrust Litigation

Case Number

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

September 18, 2019

Recent Articles By J.

February 15, 2022
CVS Wants Consolidated Drug Pricing Suit In Arbitration
February 03, 2022
GAO Says VA Reasoning Was Sound In $735M IT Deal
January 24, 2022
Pharma Cos. Get Bystolic Generic Delay Claims Tossed
January 18, 2022
Teva, Glenmark Must Face Price-Fixing Suit At Same Trial
January 12, 2022
Sutter Antitrust Trial Must Go On Despite COVID, Judge Told
January 04, 2022
Generic Drug Cos., Takeda Escape Gout Drug Antitrust Suit
December 02, 2021
FTC Pushing Caris Life Sciences For Merger Challenge Docs
November 17, 2021
Consumer Counsel Gets $115M From EpiPen Settlement
November 10, 2021
FTC Judge Says Amici Offer Nothing New In Illumina Case
November 09, 2021
COVID Apps Can't Force Action Against Apple, FTC Says